@article{96603,
  keywords = {Hansen disease, Mycobacterium leprae, QcrB inhibitors, Bacteria, leprosy, telacebec, terminal oxidase, Tuberculosis and other mycobacteria},
  author = {Lahiri R and Adams L and Thomas S and Pethe K},
  title = {Sensitivity of Mycobacterium leprae to Telacebec.},
  abstract = {<p>The treatment of leprosy is long and complex, benefiting from the development of sterilizing, rapidly-acting drugs. Reductive evolution made Mycobacterium leprae exquisitely sensitive to Telacebec, a phase 2 drug candidate for tuberculosis The unprecedented potency of Telacebec against M. leprae warrants further validation in clinical trials.</p>
},
  year = {2022},
  journal = {Emerging infectious diseases},
  volume = {28},
  pages = {749-751},
  month = {03/2022},
  issn = {1080-6059},
  url = {https://wwwnc.cdc.gov/eid/article/28/3/pdfs/21-0394.pdf},
  doi = {10.3201/eid2803.210394},
  language = {eng},
}